Sara Healy

Mar 28, 2024 | bioprocessintl.com | Sara Healy

Fundação Oswaldo Cruz (Fiocruz) and Caring Cross, a non-profit aiming at developing and improving access to advanced medicines across the globe, announced they will collaborate to drive local manufacturing of chimeric antigen receptor (CAR-T) cell and stem cell-based gene therapies in Brazil and Latin American. According to Fiocruz, such an arrangement will be very attractive for the Brazilian national public health system.

Mar 20, 2024 | bioprocessintl.com | Dan Stanton |Shreeyashi Ojha |Sara Healy

Through the acquisition of Spark therapeutics in 2019, Roche propelled itself into gene therapy space and hasn’t looked back. Reporting from the December 2023 Cell & Gene Therapy Manufacturing & Commercialization Europe conference in Ireland, this eBook addresses the production of next-generation adenoassociated virus (AAV)–based products. Specifically, the Swiss biopharmaceutical giant hopes to break through the manufacturing limitations that have limited the reach of such lifesaving treatments.

Dec 20, 2023 | bioprocessintl.com | Sara Healy

Gavi pushes to improve vaccine manufacturing in Africa by Sara Healy Wednesday, December 20, 2023  4:09 am Gavi has launched the African Vaccine Manufacturing Accelerator (AVMA) program focused on growing Africa’s manufacturing base with up to $1 billion in contributions.

Dec 11, 2023 | bioprocessintl.com | Sara Healy

AGC Bio and Immunocore ink bispecific deal Contract development manufacturing organization (CDMO) AGC Biologics will use its recently expanded Heidelberg, Germany facility to help service a bispecific collaboration with Immunocore.

Dec 4, 2023 | bioprocessintl.com | Sara Healy

With reworked gov grant, it’s back to business for Valneva Scotland plant Scottish Enterprise has scaled back a $25 million grant to Valneva after the French firm reduced its workforce on the back of a drop in COVID vaccine demand.